{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:22:35Z","timestamp":1792786955145,"version":"4.5.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Department of Medical Oncology & Hematology, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada","id":[{"id":"https:\/\/ror.org\/03zayce58","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004085","name":"Ministry of Education, Science and Technology (MEST)","doi-asserted-by":"publisher","award":["NRF-2015R1A2A1A10054579"],"award-info":[{"award-number":["NRF-2015R1A2A1A10054579"]}],"id":[{"id":"10.13039\/501100004085","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea (NRF)","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009950","name":"Ministry of Education","doi-asserted-by":"publisher","award":["NRF-2011-0030034"],"award-info":[{"award-number":["NRF-2011-0030034"]}],"id":[{"id":"10.13039\/100009950","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Queen Elizabeth II Graduate Scholarship for Science and Technology (University of Toronto, Canada)"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.leukres.2017.06.009","type":"journal-article","created":{"date-parts":[[2017,6,17]],"date-time":"2017-06-17T08:31:42Z","timestamp":1497688302000},"page":"142-148","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy"],"prefix":"10.1016","volume":"59","author":[{"given":"TaeHyung","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Tyndel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaolei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaesook","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seunghyun","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Szardenings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey H.","family":"Lipton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeoung-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis","family":"Kim Dong Hwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5405","key":"10.1016\/j.leukres.2017.06.009_bib0005","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.leukres.2017.06.009_bib0010","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"19","key":"10.1016\/j.leukres.2017.06.009_bib0015","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.leukres.2017.06.009_bib0020","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.leukres.2017.06.009_bib0025","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.leukres.2017.06.009_bib0030","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"26","key":"10.1016\/j.leukres.2017.06.009_bib0035","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1056\/NEJMoa1004095","article-title":"Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia","volume":"363","author":"Preudhomme","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.leukres.2017.06.009_bib0040","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"10","key":"10.1016\/j.leukres.2017.06.009_bib0045","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.leukres.2017.06.009_bib0050","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1182\/blood-2015-08-660977","article-title":"Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients","volume":"127","author":"Deininger","year":"2016","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2017.06.009_bib0055","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2012-05-431379","article-title":"BCR-ABL1 compound mutations in tyrosine kinase inhibitor-resistant CML: frequency and clonal relationships","volume":"121","author":"Khorashad","year":"2013","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2017.06.009_bib0060","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccr.2014.07.006","article-title":"BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia","volume":"26","author":"Zabriskie","year":"2014","journal-title":"Cancer Cell"},{"issue":"23","key":"10.1016\/j.leukres.2017.06.009_bib0065","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"6127","key":"10.1016\/j.leukres.2017.06.009_bib0070","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1126\/science.1235122","article-title":"Cancer genome landscapes","volume":"339","author":"Vogelstein","year":"2013","journal-title":"Science"},{"issue":"22","key":"10.1016\/j.leukres.2017.06.009_bib0075","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Cancer Genome Atlas Research","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"22","key":"10.1016\/j.leukres.2017.06.009_bib0080","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2017.06.009_bib0085","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/ng.2698","article-title":"Exome sequencing identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia","volume":"45","author":"Sakaguchi","year":"2013","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.leukres.2017.06.009_bib0090","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/nar\/29.1.308","article-title":"dbSNP: the NCBI database of genetic variation","volume":"29","author":"Sherry","year":"2001","journal-title":"Nucleic Acids Res."},{"issue":"12","key":"10.1016\/j.leukres.2017.06.009_bib0095","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","article-title":"Clonal architecture of secondary acute myeloid leukemia","volume":"366","author":"Walter","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.leukres.2017.06.009_bib0100","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1038\/bcj.2013.54","article-title":"ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia","volume":"3","author":"Menezes","year":"2013","journal-title":"Blood Cancer J."},{"issue":"3","key":"10.1016\/j.leukres.2017.06.009_bib0105","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/leu.2010.298","article-title":"A deep-sequencing study of chronic myeloid leukemia patients in blast crisis (BC-CML) detects mutations in 76.9% of cases","volume":"25","author":"Grossmann","year":"2011","journal-title":"Leukemia"},{"issue":"12","key":"10.1016\/j.leukres.2017.06.009_bib0110","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1038\/leu.2014.272","article-title":"Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status","volume":"28","author":"Schmidt","year":"2014","journal-title":"Leukemia"},{"issue":"21","key":"10.1016\/j.leukres.2017.06.009_bib0115","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1182\/blood-2010-06-292433","article-title":"CBL, CBLB, TET2, ASXL1, and IDH1\/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia","volume":"117","author":"Makishima","year":"2011","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.leukres.2017.06.009_bib0120","doi-asserted-by":"crossref","first-page":"2648","DOI":"10.1093\/bioinformatics\/btr462","article-title":"Exome sequencing-based copy-number variation and loss of heterozygosity detection: ExomeCNV","volume":"27","author":"Sathirapongsasuti","year":"2011","journal-title":"Bioinformatics"},{"issue":"2","key":"10.1016\/j.leukres.2017.06.009_bib0125","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/leu.2015.264","article-title":"Clonal dynamics in a single AML case tracked for 9 years reveals the complexity of leukemia progression","volume":"30","author":"Kim","year":"2016","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.leukres.2017.06.009_bib0130","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1093\/bioinformatics\/btt750","article-title":"Subclonal variant calling with multiple samples and prior knowledge","volume":"30","author":"Gerstung","year":"2014","journal-title":"Bioinformatics"},{"issue":"35","key":"10.1016\/j.leukres.2017.06.009_bib0135","doi-asserted-by":"crossref","first-page":"4702","DOI":"10.1200\/JCO.2011.35.5719","article-title":"Adverse prognostic impact of abnormal lesions detected by genome-wide single nucleotide polymorphism array-based karyotyping analysis in acute myeloid leukemia with normal karyotype","volume":"29","author":"Yi","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.leukres.2017.06.009_bib0140","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/ajh.23281","article-title":"A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia","volume":"87","author":"Huh","year":"2012","journal-title":"Am. J. Hematol."},{"issue":"11","key":"10.1016\/j.leukres.2017.06.009_bib0145","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s00277-011-1195-2","article-title":"Genome-wide high density single-nucleotide polymorphism array-based karyotyping improves detection of clonal aberrations including der(9) deletion, but does not predict treatment outcomes after imatinib therapy in chronic myeloid leukemia","volume":"90","author":"Huh","year":"2011","journal-title":"Ann. Hematol."}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617304629?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212617304629?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T20:18:03Z","timestamp":1656188283000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212617304629"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":29,"alternative-id":["S0145212617304629"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2017.06.009","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exome sequencing reveals DNMT3A and ASXL1 variants associate with progression of chronic myeloid leukemia after tyrosine kinase inhibitor therapy","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2017.06.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}